Neurodegeneration, sleep, and cerebral energy metabolism: A testable hypothesis

Journal of Geriatric Psychiatry and Neurology

Volumn 10, Issue 1, 1997, Pages 29-32

  Mamelak, Mortimer ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b BAYCREST CENTRE FOR GERIATRIC CARE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYBUTYRIC ACID;

ALZHEIMER DISEASE; ARTICLE; BRAIN METABOLISM; CELL METABOLISM; ENERGY CONSERVATION; HUMAN; NERVE DEGENERATION; PARKINSON DISEASE; PRIORITY JOURNAL; SLEEP; SLEEP PATTERN; SLOW BRAIN WAVE;

EID: 0030895326     PISSN: 08919887     EISSN: None     Source Type: Journal    
DOI: 10.1177/089198879701000106     Document Type: Article

References (42)

1. Lutz PL, LaManna JC, Adams MR, Rosenthal M. Cerebral resistance to anoxia in the marine turtle. Respir Physiol 1980; 41:241-251.
2. Sick TJ, Rosenthal M, LaManna JC, Lutz PL. Brain potassium homeostasis, anoxia and metabolic inhibition in turtles and rats. Am J Physiol 1982; 243:R281-R288.
3. Mata M, Fink DJ, Gainer H, et al. Activity-dependent energy metabolism in rat posterior pituitary primarily reflects sodium pump activity. J Neurochem 1980; 34:213-215.
4. Heller HC, Krilowicz BL, Kilduff TS. Neural mechanisms controlling hibernation. In: Malan A, Canquilhem B, eds. Living in the cold. 2nd International Symposium. London: John Libbey Eurotext Ltd., 1989:447-459.
5. Frerichs KU, Kennedy C, Sokoloff L, Hallenbeck JM. Local cerebral blood flow during hibernation, a model of natural tolerance to cerebral ischemia. Cereb Blood Flow Metab 1994; 14:193-205.
6. Pakhotin PI, Pakhotina ID, Belousov AB. The study of brain slices from hibernating mammals in vitro and some approaches to the analysis of hibernation problems in vivo. Prog Neurobiol 1993; 40:123-161.
7. Buchsbaum MS, Gillin JC, Wu J, et al. Regional cerebral glucose metabolic rate in human sleep assessed by position emission tomography. Life Sci 1989; 45:1349-1356.
8. 18F]2-fluro-2-deoxy-D-glucose method. Brain Res 1990; 513:136-143.
9. Maquet P, Dive D, Salmon E, et al. Cerebral glucose utilization during stage 2 sleep in man. Brain Res 1992; 571:149-153.
10. 2 metabolism and cerebral blood flow in humans during deep and rapid eye movement sleep. J Appl Physiol 1991; 70:2597-2601.
11. Stryer L. Biochemistry. 3rd Ed. New York: W.H. Freeman, 1988:627-645.
12. Pazdernik T, Cross R, Nelson S, et al. Is there an energy conservation "system" in brain that protects against the consequences of energy depletion? Neurochem Res 1994; 19: 1393-1400.
13. Williams RL, Karacan I, Hirsch CJ. EEG of human sleep. Clinical Applications. New York: Wiley, 1974.
14. Feinberg I. Schizophrenia: caused by a fault-in programmed synaptic elimination during adolescence? J Psychiatr Res 1983; 17:319-334.
15. Bliwise DL. Sleep in normal aging and dementia. Sleep 1993; 16:40-81.
16. Vitiello MV, Prinz PN, Williams DE, et al. Sleep disturbances in patients with mild-stage Alzheimer's disease. J Gerontol 1990; 45:M131-M138.
17. Prinz P, Poceta S, Vitiello MV. Sleep in the dementing disorders. In: Boller F, Grafman J, eds. Handbook of neuropsychology. Vol. 4. Amsterdam: Elsevier Science, 1990:335-347.
18. Hof PR, Morrision JH. The cellular basis of cortical disconnection in Alzheimer's disease and related dementing conditions. In: Terry R, Katzman R, Bick KL, eds. Alzheimer disease. New York: Raven Press, 1994:197-229.
19. Beal MF. Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses. Ann Neurol 1992; 31:119-130.
20. Hoyer S. Brain oxidative energy and related metabolism, neuronal stress and Alzheimer's disease: a speculative synthesis. J Geriatr Psychiatry Neurol 1993; 6:3-13.
21. Hamos JE, Obias B, Pulashi-Salo D, et al. Expression of heat shock proteins in Alzheimer's disease. Neurology 1991; 4:345-350.
22. Royston MC, Rothwell NJ, Roberts GW. Alzheimer's disease: pathology to potential treatments? Trends Pharmacol Sci 1992; 13:131-133.
23. Mrak RE, Sheng JG, Griffin WST. Glial cytokines in Alzheimer's disease: review and pathogenic implications. Hum Pathol 1995; 26:816-823.
24. Horsburgh K, Saitoh T. Altered signal transduction in Alzheimer disease. In: Terry RD, Katzman R, Bick KL, eds. Alzheimer disease. New York: Raven Press, 1994:387-404.
25. Bush ML, Miyashiro JS, Ingram VM. Activation of a neurofilament kinase, a tau kinase, and a tau phosphatase by decreased ATP levels in nerve growth factor-differentiated PC-12 cells. Proc Natl Acad Sci U S A 1995; 92:1861-1865.
26. Pettegrew JW, McClure RJ, Kanfer JN, et al. The role of membranes and energetics in Alzheimer Disease. In: Terry RD, Katzman R, Bick KL, eds. Alzheimer disease. New York: Raven Press, 1994:369-386.
27. 31P NMR profiles of Alzheimer's disease and multiple subcortical infarct dementia. Neurology 1989; 39:1423-1427.
28. Murphy DGM, Bottomley PA, Salerno JA, et al. An in vivo study of phosphorous and glucose metabolism in Alzheimer's disease using magnetic resonance spectroscopy and PET. Arch Gen Psychiatry 1993; 50:341-349.
29. Blass JP, Gibson GE, Sheu KR, Black RS. Mitochondria, aging, and neurological disease. In: Zatta P, Nicolini M, eds.Non-neural cells in Alzheimer's disease. Singapore: World Scientific, 1995:95-107.
30. Bowling AC, Mutisya EM, Walker LC, et al. Age-dependent impairment of mitochondrial function in primate brain. J Neurochem 1993; 60:1964-1967.
31. Reiman EM, Caselli RJ, Yun LS, et al. Preclinical evidence of Alzheimer's disease in persons homozygous for the ∈4 allele for apolipoprotein E. N Engl J Med 1996; 334:752-758.
32. Markesbery WR, Ehmann WD. Brain trace elements in Alzheimer disease. In: Terry RD, Falzman R, Bick KL, eds. Alzheimer disease. New York: Raven Press, 1994:353-367.
33. Furtado JCS, Mazurek MF. MPTP-induced neurotoxicity and the quest for a preventive therapy for Parkinson's disease. Can J Neurol Sci 1991; 18:77-82.
34. Schapira AHV, Cooper JM, Dexter D, et al. Mitochondrial complex 1 deficiency in Parkinson's disease. J Neurochem 1990; 54:823-827.
35. Fahn S, Cohen G. The oxidant stress hypothesis in Parkinson's disease: evidence supporting it. Ann Neurol 1992; 32:804-812.
36. Mamelak M. Gammahydroxybutyrate: an endogenous regulator of energy metabolism. Neurosci Biobehav Rev 1989; 13:187-198.
37. Wolfson LI, Sakurada O, Sokoloff L. Effects of butyrolactone on local cerebral glucose utilization in the rat. J Neurochem 1977; 29:777-783.
38. MacMillan V. The effects of gamma-hydroxybutyrate and gamma-butyrotactone upon the energy metabolism of the normoxic and hypoxic rat brain. Brain Res 1978; 146:177-187.
39. Lavyne MH, Hariri RJ, Tankosic T, Babiak T. Effect of low dose butyrotactone therapy on forebrain neuronal ischemia in the unrestrained, awake rat. Neurosurgery 1983; 12:430-434.
40. Meerson F, Kagan V, Prilipko L, et al. Inhibition of lipid peroxidation action with ionol and gammahydroxybutyric acid in emotional pain stress. Biull Eksp Biol Med 1979; 88:404-406.
41. Azczek R, Nelson M, Coyle J. Kainic acid neurotoxicity and seizures. Neuropharmacology 1981; 20:183-189.
42. Hochachka PW, Guppy M. Metabolic arrest and the control of biological time. Cambridge: Harvard University Press, 1987.